20 results about "Basal cell carcinoma" patented technology

Presented herein are systems and methods for detecting basal-cell carcinoma (BCC) in biomedical images of skin lesions. A computing system may identify, for a first subject at risk of BCC in a first lesion on a region of an epidermis: (i) a first biomedical image of an outer layer of the region on the epidermis of the first subject acquired in accordance with dermoscopy, and (ii) a plurality of second biomedical images of at least one inner layer in the region on the epidermis of the first subject acquired in accordance with reflection confocal microscopy (RCM). The computing system may apply the first biomedical image and the plurality of second biomedical images to a model architecture. The computing system may generate, based on applying to the model architecture, a score indicating a likelihood of BCC in the first lesion.

Disclosed herein are analogues of itraconazole that are potent hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

Disclosed herein are solid forms (e.g., crystalline forms) of 4-(5-cyclopropyl-4-piperazin-1-yl-pyrido[3,4-d]pyrimidin-2-yl)-9H-pyrido[2,3-b]indole (Compound 1), as well as compositions, pharmaceutical compositions, kits, methods, and uses thereof. The compounds disclosed herein are inhibitors of atypical protein kinase C (aPKC), and therefore, their solid forms are useful for treating and / or preventing basal cell carcinoma.

The present invention relates to a compound of patidegib, a process for the preparation thereof, and methods of treatment of BCC and / or preventing, delaying and / or inhibiting the formation of new basal cell carcinoma in a subject in need, by administering the compound of this invention.

Methods for inducing basal cell carcinoma (BCC) or BCC tumors, as well as an inducible non-human animal models of BCC, are defined herein. The methods and animal models comprise targeting Ptch1 and / or a tumor suppressor gene via conditional expression of one or more short hairpin RNAs (shRNAs) in the skin of said animals.

Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.

The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

Disclosed herein is a method of treating and / or preventing basal cell carcinoma lesions, the method comprising topically administering to a subject in need thereof a pharmaceutical composition comprising patinigib, or a pharmaceutically acceptable salt thereof, where (i) the subject must have at least 6 facial BCC lesions; or (ii) the subject must have a genetically mutated PTCH; or (iii) the subject must have at least 6 BCC lesions and a genetically mutated PTCH.

The present disclosure is based on the development of improved clinical protocols for administering an anti-cancer peptide having the sequence of SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof ("Peptide A"), to a subject (e.g., for the treatment of a skin cancer, such as basal cell carcinoma (BCC)). Methods provided herein allow for the safe and effective treatment of skin cancers, including BCC, in a minimally invasive manner. In certain embodiments, methods provided herein allow for administration of Peptide A to a skin cancer lesion (e.g., BCC lesion) on a subject with no significant treatment-related adverse events (TRAEs), e.g, TRAEs such as burning and / or pain at the injection site.

Disclosed herein is a method of treatment and / or prevention basal cell carcinoma lesions, comprising topically administering a pharmaceutical composition comprising patidegib or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject has a genetic mutation PTCH.

Methods for treating and / or prognosing breast cancer are provided. The method includes determining an Immunescore (IS) for gene sets selected from an immunological signature gene set, wherein the IS is based on an immunological model, determining a Proliferative Index (PI) for gene sets selected from an oncogenic signature gene set, wherein the PI is based on a tumor-intrinsic model; and integrating the IS and the PI into an Integrated model to stratify subjects and identify a high-risk clinical group. The immunological model is trained (IS) in basal and HER2+ tumors, and the tumor-intrinsic model (PI) is trained in immune-depleted tumors.

The present invention discloses the application of a derivative with simultaneous substitution at the meso-position and 2-position of hypocrellin as a photodynamic drug in the photodynamic therapy of various tumors. The maximum absorption wavelength of such derivatives is around 630 nm, and the molar extinction coefficient can reach 20,000 - 40,000 M-1 cm-1, showing strong light absorption ability in the phototherapy window; under photosensitizing conditions, it can efficiently generate reactive oxygen species such as singlet oxygen. Such derivatives can efficiently kill a variety of tumor cells, such as esophageal cancer, gastric cancer, lung cancer, liver cancer, cholangiocarcinoma, and colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer, and glioblastoma cells related to head and neck tumors; basal cell carcinoma, squamous cell carcinoma, cutaneous T-cell lymphoma, and melanoma cells related to skin tumors; prostate cancer and bladder cancer cells related to genitourinary tumors. At the same time, such derivatives have good enrichment effects in various tumor cells, can specifically accumulate in tumor cells or tissues, and can locate the position of tumor tissues through the self-fluorescence of the photosensitizer, for fluorescence-guided surgical resection of tumors. Under the same conditions, the derivatives in the present invention have higher photodynamic effects in treating tumors than commercial porphyrin-based photosensitizing drugs.

A system for classification of basal cell carcinoma (BCC) and a method of classifying basal cell carcinoma (BCC) may be provided, the system comprising a processing module configured to receive an input image sequence comprising a plurality of images; and a prediction module coupled to the processing module, the prediction module comprising a hierarchical ensemble structure of a plurality of classification models; wherein the processing module is configured to process each image as a whole image to obtain a plurality of first sub-sections and to further process each first sub-section to obtain a corresponding plurality of second sub-sections; further wherein the processing module is configured to transmit the each first sub-section to a first classification model of the prediction module trained to process the first sub-sections and to transmit each of the corresponding plurality of second sub- sections to a second classification model of the prediction module trained to process the second sub-sections, further wherein the prediction module is configured to determine a probability of BCC of the each image of the input image sequence based on a plurality of respective block prediction results corresponding to the first sub-sections of the each image; and further wherein the prediction module is configured to determine a BCC classification of the input image sequence based on the determined probability of BCC of each image of the input image sequence.

The invention relates to a hypocrellin 2-site amino substituted derivative (formula I) or ethylenediamine substituted derivative (formula II and formula III) as a photodynamic drug for treating the following tumors: esophageal cancer, gastric cancer, lung cancer, liver cancer, bile duct cancer and colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer and brain glioma cells related to head, neck and face tumors; basal cell carcinoma, squamous skin carcinoma, skin T cell lymphoma and melanoma cells related to skin tumors; prostate cancer and bladder cancer cells related to genitourinary system tumors. Meanwhile, the derivative can locate the position of a tumor tissue through self-fluorescence and is used for fluorescence-guided tumor operation excision.

The present invention relates to a compound of patidegib, a process for the preparation thereof, and methods of treatment of BCC and / or preventing, delaying and / or inhibiting the formation of new basal cell carcinoma in a subject in need, by administering the compound of this invention.

The method of marking a cutaneous tissue sample for pathological study uses a generated dermoscopy heatmap image in which different colors shown in the heatmap image represent differing degrees of likelihood of malignant or cancerous tissue (e.g., melanoma, basal cell carcinoma or squamous cell carcinoma) or atypical melanocytic nevus of uncertain malignant potential (AMNUMP) (e.g., atypical nevi, spitz nevi, and the like) in a patient's target skin lesion of concern (TSLC) and / or in the patient's pigmented skin lesion of concern (PSLC). The patient's target skin lesion of concern and / or in the patient's pigmented skin lesion of concern is marked in vivo or ex vivo with pigment (e.g., ink, dye, or the like) in areas of interest indicated by the heatmap image. A cutaneous tissue sample is then removed by physical biopsy from the patient.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The present disclosure is based on the development of improved clinical protocols for administering an anti-cancer peptide having the sequence of SEQ ID NO: 1, or a pharmaceutically acceptable salt thereof (“Peptide A”), to a subject (e.g., for the treatment of a skin cancer, such as basal cell carcinoma (BCC)). Methods provided herein allow for the safe and effective treatment of skin cancers, including BCC, in a minimally invasive manner. In certain embodiments, methods provided herein allow for administration of Peptide A to a skin cancer lesion (e.g., BCC lesion) on a subject with no significant treatment-related adverse events (TRAEs), e.g., TRAEs such as burning and / or pain at the injection site.

Disclosed herein are methods for treating and / or preventing basal cell carcinoma lesions, comprising topically administering a pharmaceutical composition comprising pasidegib or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein (i) the subject must have at least six facial BCC lesions, or (ii) the subject must have genetically mutated PTCH, or (iii) the subject must have at least six BCC lesions and genetically mutated PTCH.

Disclosed herein are solid forms (e.g., crystalline forms) of 4-(5-cyclopropyl-4-piperazin-1-yl-pyrido [3, 4-d] pyrimidin-2-yl)-9H-pyrido [2, 3-b] indole (Compound 1) and compositions, pharmaceutical compositions, kits, methods and uses thereof. The compounds disclosed herein are inhibitors of atypical protein kinase C (aPKC), and thus their solid forms are useful for the treatment and / or prevention of basal cell carcinoma.